News Column

22nd Century Group Reports FDA Notice Allowance for Regulating Nicotine in Tobacco Products

July 9, 2014

22nd Century Group reported that the United States Patent and Trademark Office has issued a Notice of Allowance for technology that decreases or increases nicotine production and levels in tobacco plants by using nucleic acids derived from a transcription factor gene identified as NbTF7 - also known as NbARF1.

ANbTF7 simultaneously regulates the expression of multiple nicotine biosynthesis genes.

According to a release from the group, the transcription factor technology is one of several 22nd Century patent families representing the company's second-generation technology for modifying the content of nicotine and other nicotinic alkaloids in the tobacco plant.

22nd Century's Vice President of Research and Development, Dr. Michael Moynihan stated, "We are very pleased that the USPTO has allowed this patent. Modification of transcription factor expression provides a means of regulating the entire nicotine pathway. We believe there will be tremendous commercial opportunities for both our very low nicotine and our higher nicotine tobacco varieties."

22nd Century is a plant biotechnology company.

More information and complete details:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Health & Beauty Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters